Works matching AU Sung Hee Choi

Results: 222
    1
    2
    3
    4
    5

    Lipid‐Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double‐Blind, Parallel, Multicenter, Phase 3 Clinical Trial.

    Published in:
    Clinical Cardiology, 2025, v. 48, n. 5, p. 1, doi. 10.1002/clc.70138
    By:
    • Ki, You‐Jeong;
    • Kim, Weon;
    • Lee, Ki Hong;
    • Han, Sang‐Jin;
    • Kim, Yong‐Hyun;
    • Doh, Joon‐Hyung;
    • Kim, Tae Nyun;
    • Chung, Choon Hee;
    • Kim, Do Young;
    • Cho, Jin‐Man;
    • Yoon, Hyuck‐Jun;
    • Jeong, In‐Kyung;
    • Park, Sungha;
    • Song, Kee‐Ho;
    • Yu, Cheol Woong;
    • Cho, Deok‐Kyu;
    • Choi, Sung Hee;
    • Oh, Seung‐Jin;
    • Shin, Sanghoon;
    • Jeong, Hyeonju
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21

    Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2743, doi. 10.1111/dom.15164
    By:
    • Park, Hyeong Kyu;
    • Kim, Kyoung‐Ah;
    • Min, Kyung‐Wan;
    • Sohn, Tae‐Seo;
    • Jeong, In Kyung;
    • Ahn, Chul Woo;
    • Kim, Nan‐Hee;
    • Park, Ie Byung;
    • Cho, Ho Chan;
    • Chung, Choon Hee;
    • Choi, Sung Hee;
    • Park, Kang Seo;
    • Yang, Seoung‐Oh;
    • Lee, Kwan Woo
    Publication type:
    Article
    22

    Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2096, doi. 10.1111/dom.15080
    By:
    • Yang, Ye Seul;
    • Min, Kyung Wan;
    • Park, Seok‐O;
    • Kim, Kyung‐Soo;
    • Yu, Jae Myung;
    • Hong, Eun‐Gyoung;
    • Cho, Sung Rae;
    • Won, Kyu Chang;
    • Kim, Yong Hyun;
    • Oh, Seungjoon;
    • Choi, Sung Hee;
    • Koh, Gwanpyo;
    • Huh, Wan;
    • Kim, Su Young;
    • Park, Kyong Soo
    Publication type:
    Article
    23

    Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1865, doi. 10.1111/dom.15046
    By:
    • Kwak, Soo Heon;
    • Han, Kyung Ah;
    • Kim, Kyung‐Soo;
    • Yu, Jae Myung;
    • Kim, EunSook;
    • Won, Jong Chul;
    • Kang, Jun Goo;
    • Chung, Choon Hee;
    • Oh, Seungjoon;
    • Choi, Sung Hee;
    • Won, Kyu Chang;
    • Kim, Sin Gon;
    • Cho, Seung Ah;
    • Cho, Bo Young;
    • Park, Kyong Soo
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection.

    Published in:
    Clinical Endocrinology, 2016, v. 85, n. 3, p. 459, doi. 10.1111/cen.13029
    By:
    • Moon, Jae Hoon;
    • Choi, June Young;
    • Jeong, Woo‐Jin;
    • Ahn, Soon‐Hyun;
    • Lee, Won Woo;
    • Kim, Kyoung Min;
    • Choi, Sung Hee;
    • Lim, Soo;
    • Park, Young Joo;
    • Yi, Ka Hee;
    • Park, Do Joon;
    • Jang, Hak Chul
    Publication type:
    Article
    50